Track 1: Metabolic Syndrome

Metabolic syndrome is a medical disorder that may lead to cardiovascular disease and diabetes. Metabolic syndrome is a Group of conditions  increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels that occur together, increasing your risk of heart disease, stroke and diabetes. Genetic factors influence each individual component of the syndrome, and the syndrome itself. A family history that includes type 2 diabetes, hypertension, and early heart disease greatly increases the chance that an individual will develop the metabolic syndrome. Most of the disorders associated with metabolic syndrome have no symptoms, although a large waist circumference is a visible sign. If your blood sugar is very high, you might experience signs and symptoms of diabetes including increased thirst and urination, fatigue, and blurred vision.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22 2016; 3^rd International conference on Gynecology and Obstetrics October 17-19 2016 Dubai, UAE; International Conference on Metabolic Syndromes October 20-22 2016, UAE; Pregnancy Summit and Child Health August 29-31 2016 Brazil; 4th International Conference on Weight Loss and Fitness Expo November 21-23, 2016 Dubai, UAE; 2nd Global Conference of the European Society of Contraception and Reproductive Health November 12-16, 2015, Switzerland; American Society for Reproductive Medicine Congress October 17-21, 2015 Baltimore, USA;  22nd IFFS World Congress on Fertility September 21-25, 2016 India; 13th Congress of the European Federation of Sexology (EFS) May 25-28, 2016 CROATIA;  Reproductive Health November 12-16, 2015  Chicago, USA; Obesity Medical Conferences  Nov 14-15, 2016 Dubai, UAE; Endocrinology Conferences October 10-12, 2016 Manchester, UK

Track 2: Endocrine Disorders

Endocrine glands are a group of glands in the body which secrete hormones. The endocrine system influences how your heart beats, how your bones and tissues grow, even your ability to make a baby. It plays a vital role in whether or not you develop diabetes, thyroid disease, growth disorders, sexual dysfunction, and a host of other hormone-related disorders. Endocrine disorders are typically grouped into two categories:

• Endocrine disease that results when a gland produces too much or too little of an endocrine hormone, called a hormonal imbalance.
• Endocrine disease due to the development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect hormone levels.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016; 2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA; 5^th International Conference on Diabetes and Clinical Endocrinology October 31- 02 November 2016, San Antonio, USA; 6^th  International Conference on Endocrinology December 05-07,2016, Dalla, USA; International Conference on Thyroid Disorders and Treatment February 29-March 02, 2016 Philadelphia, USA;  ESE Basic Course on Endocrine and Neuroendocrine Cancer, February 17-19 2016 Portugal; EndoBridge 15–18 October 2015,Turkey; 86^th Annual Meeting of the American Thyroid Association September 21-25 2016 Colorado; 3^rd Steroid Research Congress 15-18 Nov 2015 USA; 85^th Annual Meeting of the American Thyroid Association 21–25 September 2016, USA; Endocrinology Conferences October 10-12, 2016 Manchester, UK; Obesity Conferences Nov 14-15, 2016 Dubai, UAE.

Track 3: Insulin Resistance Syndrome

Insulin resistance is a condition in which the cells of the body become resistant to the hormone insulin. Insulin resistance may be part of the metabolic syndrome, and it has been associated with higher risk of developing heart disease. Insulin resistance precedes the development of type 2 diabetes (T2D).Insulin resistance is associated with other medical conditions, including liver, arteriosclerosis, acanthuses, skin tags, and reproductive abnormalities in women. When the body produces insulin under conditions of insulin resistance , the cells in the body are resistant to the insulin and are unable to use it as effectively, leading to high blood sugar. Beta cells in the  pancreas subsequently increase their production of insulin, further contributing to a high blood insulin level. This often remains undetected and can contribute to a diagnosis of Type 2 diabetes or latent autoimmune diabetes of adults.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016; 2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA; 5^th International Conference on Diabetes and Clinical Endocrinology October 31- 02 November 2016, San Antonio, USA; 15^th Global Diabetes Summit and Medicare Expo November 14-16, 2016 Dubai, UAE; 8th Euro Global Diabetes Summit and Medicare Expo  July 14-16, 2016 Birmingham, UK;8th Euro Global Diabetes Summit and Medicare Expo  July 14-16, 2016 Birmingham, UK; International Conference on Pancreatic and Colorectal Cancer March 29-30 2016, USA; 5^th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension November 5-7 2016, Turkey; Obesity Medical Conferences  Nov 14-15, 2016 Dubai, UAE; 3^rd Steroid Research Congress 15-18 Nov 2015 USA; 11^th Asia Pacific Diabetes Conference and Expo July 11-13, 2016 Australia; 7^th ESE Clinical Update, January 15-16 2016 UAE.

Track 4: Cardiovascular Disorders

Cardiovascular disease refers to more than one disease of the circulatory system including the heart and blood vessels, whether the blood vessels are affecting the lungs, the brain, kidneys or other parts of the body. Coronary artery disease, stroke, and peripheral artery disease involve atherosclerosis. This may be caused by high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol consumption, among others. High blood pressure results in 13% of CVD deaths, while tobacco results in 9%, diabetes 6%, lack of exercise 6% and obesity 5%. The effect of the use of aspirin in people who are otherwise healthy is of unclear benefit. The United States Preventive Services Task Force recommends against its use for prevention in women less than 55 and men less than 45 years old; however, in those who are older it is recommends in some individuals. Treatment of those who have CVD improves outcomes. Cardiovascular diseases are the leading cause of death globally. Coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females. Most cardiovascular disease affects older adults. In the United States 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016; 2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA; 15^th Global Diabetes Summit and Medicare Expo November 14-16, 2016 Dubai, UAE;  3^rd International conference on Gynecology and Obstetrics October 17-19 2016 Dubai, UAE; 5^th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension November 5-7 2016, Turkey; 86^th Annual Meeting of the American Thyroid Association September 21-25 2016 Colorado; 3^rd Steroid Research Congress 15-18 Nov 2015 USA; 85^th Annual Meeting of the American Thyroid Association 21–25 September 2016, USA; Endocrinology Conferences October 10-12, 2016 Manchester, UK; Obesity Conferences Nov 14-15, 2016 Dubai, UAE.

Track 5: Metabolic Disorders in Children

A metabolic disorder occurs when abnormal chemical reactions in the human body disrupt metabolism. When this happens, the patient may have too much of some substances, or too little of others, which are needed to stay healthy. Metabolic disorders or inborn errors of metabolism (IEM) result from a block (partial or complete) to an essential pathway in the body's metabolism. Childhood obesity has contributed to an increased incidence of type 2 diabetes mellitus and metabolic syndrome among children.  Disorders in metabolism can be inherited, in which case they are also known as inborn errors of metabolism. Inherited metabolic disorders may affect about 1 in 1,000 to 2,500 new borns. In most inherited metabolic disorders, a single enzyme is either not produced by the body at all or is produced in a form that doesn't work. The missing enzyme is like an absentee worker on the assembly line. Depending on that enzyme's job, its absence means toxic chemicals may build up, or an essential product may not be produced.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016; 2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA; Polycystic Ovarian Syndrome Conference November 16-18, 2015, USA; International Conference on Endocrinology December 05-07,2016, Dalla, USA;  5^th International Conference on Diabetes and Clinical Endocrinology October 31- 02 November 2016, San Antonio, USA;17^th ESE Postgraduate Training Course on Endocrinology, Diabetes and Metabolism November 19-22 2016 Albaniap; 7^th ESE Clinical Update, January 15-16 2016 UAE; 11^th World Congress of the European Society of Gynecology (ESG), October 21-24 2015 Czech Republic; XX1 World Congress of Gynecology and Obstetrics October 4-9 2015 Canada,  Association of Early Pregnancy Units November 3-4 2015  UK, National Cancer Research Institute Cancer Conference, November 1-4 2015 UK; Obesity Medicine Conferences Nov 14-15, 2016 Dubai, UAE; Endocrinology Conferences October 10-12, 2016 Manchester, UK.

Track 6: Inflammation and Metabolic Syndrome

Inflammation is the body's attempt at self-protection; the aim being to remove harmful stimuli, including damaged cells, irritants, or pathogens - and begin the healing process. Obesity and its comorbidities, including type 2 diabetes mellitus and cardiovascular disease, are associated with a state of chronic low-grade inflammation that can be detected both systemically and within specific tissues. Areas of active investigation focus on the molecular bases of metabolic inflammation and potential pathogenic roles in insulin resistance, diabetes, and cardiovascular disease. An increased accumulation of macrophages occurring in obese adipose tissue has emerged as a key process in metabolic inflammation. The activation of inflammatory pathways, used normally as host defence, reminds the seriousness of obesity. There is probably more than one cause for activation of inflammation. Apparently, metabolic overload evokes stress reactions, such as oxidative, inflammatory, organelle and cell hypertrophy, generating vicious cycles. Adipocyte hypertrophy, through physical reasons, facilitates cell rupture, what will evoke an inflammatory reaction.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

 International Conference on Metabolic Syndromes October 20-22,2016; 5^th International Conference on Diabetes and Clinical Endocrinology October 31- 02 November 2016, San Antonio, USA;2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA; International Conference on Endocrinology December 05-07,2016, Dalla, USA; 8th Euro Global Diabetes Summit and Medicare Expo  July 14-16, 2016 Birmingham, UK;  Endocrinology Conferences October 10-12, 2016 Manchester, UK; Obesity Medicine Conferences Nov 14-15, 2016 Dubai, UAE; ESE Basic Course on Endocrine and Neuroendocrine Cancer, February 17-19 2016 Portugal; EndoBridge 15–18 October 2015, Turkey; 7^th ESE Clinical Update, January 15-16 2016 UAE; Reproductive Health November 12-16, 2015  Chicago, USA; XX1 World Congress of Gynecology and Obstetrics October 4-9 2015 Canada; 11^th Asia Pacific Diabetes Conference and Expo July 11-13, 2016 Australia.

Track 7: Obesity, Diabetes and Metabolism

Diabetes is one of the most challenging health problems in the 21st century and one of the most common non-communicable diseases globally. It is the 4th or 5th leading cause of death in most high-income countries, with ~366 million diabetics in 2011 and an estimated 552 million in 2030. On the other hand, obesity has also become a world-wide epidemic. Obesity is a risk factor for the development of insulin resistance, with pancreatic beta cells compensating for insulin resistance by augmenting insulin secretion. The failure of beta-cells is believed to cause pre-diabetes, a condition that can lead to diabetes. "   Approximately 85% of people with diabetes are type 2, and of these, 90% are obese or overweight. Diabetes & obesity are major contributors to various other chronic diseases such as coronary artery diseases, myocardial infarction, hypertension, dyslipidemia and a number of other complicated disordersmounting evidence shows that a Mediterranean style-diet may be useful in preventing and treating chronic diseases related to mild chronic inflammation such as visceral (abdominal) obesity, metabolic syndrome, and Type 2 diabetes.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016; 2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA;12^th Diabetes Meeting and Therapeutics Expo September 29-October 1, 2016 Canada;11^th Asia Pacific Diabetes Conference and Expo July 11-13, 2016 Australia;8th Euro Global Diabetes Summit and Medicare Expo  July 14-16, 2016 Birmingham, UK; 40^th Symposium on Hormones and Cell Regulation October 08 - 11 2015 France; EndoBridge 15–18 October 2015, Turkey; 11^th Asia Pacific Diabetes Conference and Expo July 11-13, 2016 Australia; 5^th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension November 5-7 2016, Turkey; 86^th Annual Meeting of the American Thyroid Association September 21-25 2016Colorado; 85^th Annual Meeting of the American Thyroid Association 21–25 September 2016, USA; Endocrinology Conferences October 10-12, 2016 Manchester, UK; Obesity Conferences Nov 14-15, 2016 Dubai, UAE.

Track 8: Nutrition and Metabolic Responses

Nutrition & Metabolism focuses on the integration of nutrition, exercise physiology, clinical investigations, and molecular and cellular biochemistry of metabolism. The areas of interest of Nutrition & Metabolism encompass studies in obesity, diabetes, lipidemias , metabolic syndrome and exercise physiology that have an underlying basis in metabolism. Metabolic effects of dietary protein are complex. In persons with type 2 diabetes, protein ingestion results in little or no increase in plasma glucose concentrations but a stimulation of insulin and glucagon secretion. The nutritional requirements of a neonate are significantly greater than those of an adult because not only are there requirements for substrate intake to fulfill basic metabolic needs, but there are metabolic needs to maintain rapid and continued growth and development.

Related Conferences: Metabolic Syndromes Conferences| Obesity Conferences |  World Diabetes Congress |  Endocrine Conferences |  Diabetes Conference 2016  | Diabetes Conferences

International Conference on Metabolic Syndromes October 20-22,2016;2^nd Hormones and Endocrine Disorders Conference June 27-29, 2016 New Orleans, USA;  5^th International Conference on Diabetes and Clinical Endocrinology October 31- 02 November 2016, San Antonio, USA;  International Conference on Pancreatic and Colorectal Cancer March 29-30 2016, USA;6^th  International Conference on Endocrinology December 05-07,2016, Dalla, USA;  National Cancer Research Institute Cancer Conference, November 1-4 2015 UK; Obesity Medicine Conferences Nov 14-15,2016Dubai,UAE;  5^th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension November 5-7 2016, Turkey; 86^th Annual Meeting of the American Thyroid Association September 21-25 2016 Colorado; 3^rd Steroid Research Congress 15-18 Nov 2015 USA; 85^th Annual Meeting of the American Thyroid Association 21–25 September 2016, USA; Endocrinology Conferences October 10-12, 2016 Manchester, UK.

Track 9: Regulations of Energy Metabolism

Living tissue is maintained by constant expenditure of energy such as glucose, fatty acids, ketones, amino acids and other organic molecules. Regulation of energy metabolism is based on energy reserves and circulating substrates. Molecules that can be oxidized for energy are derived from storage molecules like glycogen, protein and fat and then absorbed through small intestine and carried to the cell for use in cell respiration. In mammals, excess energy is stored primarily as triglycerides, which are mobilized when energy demands arise. This mainly focuses on the role of long chain fatty acids (LCFAs) in regulating energy metabolism as ligands of peroxisome proliferator-activated receptors (PPARs). PPAR-alpha expressed primarily in liver is essential for metabolic adaptation to starvation by inducing genes for beta-oxidation and keto-genesis and by down regulating energy expenditure through fibroblast growth factor 21. PPAR-delta is highly expressed in skeletal muscle and induces genes for LCFA oxidation during fasting and endurance exercise.

Scope and Importance of Metabolic Syndrome

Metabolic syndrome is referred to a group of characteristics which occur together, causing an increased risk for a person developing type II diabetes, stroke, and cardiovascular disease. The metabolic syndrome is a public health concern because its prevalence is increasing in the United States, and it is associated with cardiovascular morbidity and mortality. Metabolic syndrome can be considered a type of warning. If it isn’t addressed, it will lead to serious health problems later down the line, most notably heart disease, stroke, and type 2 diabetes. Metabolic syndrome increases your risk of diabetes by five times and doubles your risk of blood vessel and heart disease, which can lead to heart attacks and strokes. It is important to understand about metabolic syndrome is that it is closely linked with prediabetes and insulin resistance. Insulin resistance is a condition in which the body doesn’t respond properly to insulin, a hormone produced by the pancreas that allows glucose to be distributed throughout the body to supply us with energy. As a result, the body generates more and more insulin to no avail. An estimated 1 in 6 Americans has metabolic syndrome, also known as Syndrome X and insulin resistance syndrome. The name can be a little misleading, because it’s actually not a disease in itself. Rather, it’s a cluster of risk factors that will have a serious impact on your life and health if no intervention is taken. NHANES III data showed overall prevalence in US was 22 percent, which represents ~ 47 million individuals in the United States. Approximately 7% of teens. Prevalence was nearly 7% among overweight adolescents and 29% among obese adolescents. Approximately 40% of people over age 60 meet the criteria.

Why Italy?

The prevalence of metabolic syndrome in a cohort likely representative of the Italian adult population is high. The recognition of the syndrome may represent an important challenge for physicians and healthcare and requires immediate strategies aimed to reduce level of individual metabolic traits. Metabolic syndrome was defined by the clustering of three or more of the following abnormalities: waist circumference greater than 102 cm in men and 88 cm in women; serum triglycerides level of at least 150 mg/dl (1.69 mmol/l); high-density lipoprotein cholesterol less than 40 mg/dl (1.04 mmol/l) in men and 50 mg/dl (1.29 mmol/l) in women; blood pressure greater than 130/85 mmHg; or serum glucose greater than 110 mg/dl (6.1 mmol/l). The prevalence of the metabolic syndrome was 18% in women and 15% in men. Metabolic syndrome (MetS) is highly prevalent in patients with bipolar disorder (BD). Little research has evaluated the risk profile of MetS and cardiovascular disease in different gender and age groups in these patients.

The global metabolic testing market is expected to reach $475.75 million by 2019 from $332.78 million in 2014, growing at a CAGR of 7.41% between 2014 and 2019. Rising prevalence of lifestyle diseases is the primary growth driver for this market during the forecast period (2014–2019). Moreover, technological advancements and increasing healthcare expenditure are also expected to drive market growth. However, high cost of equipment and software and reimbursement issues may hinder the growth of this market.

In this general Italian elderly population, among metabolic syndrome components, all-cause mortality is better predicted by high glucose in all subjects and in women and by low HDL cholesterol in women, whereas cardiovascular mortality is better predicted by high glucose and low HDL cholesterol in women. in Italian elderly individuals metabolic syndrome was not independently associated with total mortality, whereas it increased the risk of cardiovascular mortality only in men. In the Italian Longitudinal Study on Aging (ILSA), among metabolic syndrome features, low HDL cholesterol in men and high glucose in women were significant predictors of cardiovascular mortality.

The new study found that 34 percent of Italy adults in government health surveys conducted between 1999 and 2006 had metabolic syndrome – up from 29 percent in similar surveys done between 1988 and 1994. The researchers estimate that about 50 million Italy adults had metabolic syndrome in 1990 and 64 million had it in 2000. The number of Italians with metabolic syndrome between 1999 and 2006 was probably about 68 million.

The latest research Italy Metabolic Disorders Drugs Market Insights - 2015, provides metabolic disorders drugs market analysis, key products, and competitive landscape in Italy. The research includes metabolic disorders drugs market size estimates for 2014 in Italy, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis.

Societies associated with Metabolic Syndrome research

To encourage, educate, update and train registered medical practitioners, dieticians, qualified nurses and other appropriately qualified paramedical personnel in the field of Endocrinology and Metabolism various well-known societies/associations are working across the globe to efficiently prevent and combat the fatal disease.

• Italian Society for the Study of Inborn Metabolic Diseases and Newborn Screening
• Association of Program Directors in Endocrinology, Diabetes and Metabolism
• Italian Society of Endocrinology
• Italy - International Society of Endocrinology
• European Society of Endocrinology
• Italy - Society for Endocrinology
• Società Italiana di Endocrinologia
• European Mind & Metabolism Association
• International Society of Gynecological Endocrinology
• International Association of Endocrine Surgeons

Global Prevalence of Metabolic Syndrome

Until the first broadly applicable definition of the metabolic syndrome was proposed by the World Health Organization (WHO) in 1998  and finalized in 1999, the definition varied from one study to the next. Just as the prevalence of component conditions such as obesity, hypertension, hypergly-cemia, and dyslipidemia is critically dependent on the definition, so is the prevalence of the syndrome as a whole. The measurement technique and definition of obesity used is particularly contentious given that alternative obesity criteria for different populations have been proposed. Nearly 35 percent of all U.S. adults and 50 percent of those 60 years of age or older were estimated to have the metabolic syndrome in 2011-2012, according to a study. The metabolic syndrome is combination of health conditions (such as obesity, high blood pressure, type 2 diabetes, poor lipid profile) that contribute to cardiovascular illness and death. From 2003-2004 to 2011-2012, overall prevalence of the metabolic syndrome increased from 32.9 percent to 34.7 percent. When evaluating trends from 2007-2008 to 2011-2012, overall prevalence of the metabolic syndrome remained stable, as did prevalence trends among men and all race/ethnic groups, whereas prevalence among women decreased from 39.4 percent in 2007-2008 to 36.6 percent in 2011-2012.

From 2003 to 2012, prevalence was higher in women compared with men. When stratified by race/ethnicity, the highest prevalence was seen in Hispanics, followed by non-Hispanic whites and blacks. Prevalence increased by age groups, increasing from 18.3 percent among those 20 to 39 years of age to 46.7 percent among those 60 years or older. Among this age group, more than 50 percent of women and Hispanics had the metabolic syndrome. The authors write that the high prevalence among the oldest age group is "a concerning observation given the aging U.S. population."